Baxter International (NYSE: BAX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Baxter International reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 2 September 2026 | Foster Julie | President, Front Line Care | Shares withheld for tax | −2,098 | $25.70 | 29,164 | Form 4 |
| 2 September 2026 | Hider Andrew P. | President and CEO | Shares withheld for tax | −54,276 | $25.70 | 518,447 | Form 4 |
| 1 September 2026 | Teaff James | President, CCS | Shares withheld for tax | −750 | $25.48 | 30,370 | Form 4 |
| 2 June 2026 | Teaff James | President, CCS | Shares withheld for tax | −321 | $18.68 | 31,063 | Form 4 |
| 2 June 2026 | Wallace Steven P. | President, Adv. Surgery | Shares withheld for tax | −153 | $18.68 | 70,128 | Form 4 |
| 1 June 2026 | Zielinski Anita A | SVP, Interim CFO, CAO & Cntrlr | Grant or award | +13,426 | — | 59,714 | Form 4 |
| 5 May 2026 | Ampofo William A. II | Director | Grant or award | +12,836 | — | 30,375 | Form 4 |
| 5 May 2026 | Craig Jeffrey A | Director | Grant or award | +12,836 | — | 23,662 | Form 4 |
| 5 May 2026 | McDonnell Michael R. | Director | Grant or award | +12,836 | — | 14,647 | Form 4 |
| 5 May 2026 | Shafer David Brent | Director | Grant or award | +12,836 | — | 72,804 | Form 4 |
| 5 May 2026 | Morrison Patricia | Director | Grant or award | +12,836 | — | 42,386 | Form 4 |
| 5 May 2026 | Schlichting Nancy M | Director | Grant or award | +12,836 | — | 34,994 | Form 4 |
| 5 May 2026 | Wendell Amy McBride | Director | Grant or award | +12,836 | — | 44,235 | Form 4 |
| 5 May 2026 | Wilkes David S. | Director | Grant or award | +12,836 | — | 37,076 | Form 4 |
| 6 March 2026 | Grade Joel T. | EVP and CFO | Shares withheld for tax | −8,153 | $17.69 | 271,674 | Form 4 |
| 6 March 2026 | Rasul Reazur | EVP,Group Pres,Healthcare | Shares withheld for tax | −12,674 | $17.69 | 125,557 | Form 4 |
| 6 March 2026 | Rosenbloom David S. | EVP and General Counsel | Shares withheld for tax | −6,620 | $17.69 | 138,216 | Form 4 |
| 6 March 2026 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | Shares withheld for tax | −2,848 | $17.69 | 75,045 | Form 4 |
| 6 March 2026 | Zielinski Anita A | SVP, CAO and Controller | Shares withheld for tax | −1,932 | $17.69 | 46,281 | Form 4 |
| 2 March 2026 | Rosenbloom David S. | EVP and General Counsel | Shares withheld for tax | −1,336 | $19.69 | 144,837 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Baxter International page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.